MLKL (Human) ELISA Kit

Mixed lineage kinase domain-like pseudokinase (MLKL) is a terminal effector protein of necroptosis, an alternate form of cell death that mimics the characteristics of necrosis and apoptosis. MLKL possesses a pseudokinase domain at the C-terminus, a two-helix linker, and a four-helix bundle at the N-terminus. RIPK3 phosphorylates MLKL at threonine 357/serine 358 in this pseudokinase domain. Upon phosphorylation, MLKL undergoes a conformational change and results in the exposure of the four-helix bundle domain (4HB). Simultaneously, TAM (Tyro3, Axl, and Mer) kinase phosphorylates MLKL at tyrosine 376 and induces its oligomerization. After oligomerization, MLKL associates with chaperone proteins HSP90 and HSP70 that assist in the translocation to the plasma membrane. MLKL disrupts the integrity of the plasma membrane and subsequently causes necroptosis. Since it is the only known substrate of RIPK3 that can efficiently induce necroptosis, MLKL may be considered a promising target for anti-inflammation and anti-cancer therapies. BioVision’s MLKL (Human) ELISA kit quantitatively measures MLKL in human serum, plasma, and other biological fluids. Test samples, Standards, and Biotinylated Detection antibody are added to the wells pre-coated with capture antibody and then washed with Wash Buffer. HRP-Streptavidin is added to the plate, and post-incubation any unattached conjugates are washed off by Wash Buffer. The HRP enzymatic reaction is detected using TMB-substrate. Finally, an acidic stop solution terminates the enzymatic reaction. The color developed is directly proportional to the amount of MLKL in the sample or standard.